Barbara Rehermann, M.D.

Senior Investigator

Immunology Section, Liver Diseases Branch


Building NIHBC 10 - Clinical Center, Room 9B16C
10 Center Dr
Bethesda, MD 20892

+1 301 402 7144

Research Topics

Research Goal

The goal of this program is to better understand the immunological factors that contribute to pathogenesis of inflammatory diseases such as viral hepatitis, to assess how immune responses and chronic inflammation are regulated and to devise strategies that modulate the progression of chronic liver disease and/or induce protective immune responses.

Current Research

My research program covers two areas: 1. We study innate and adaptive immune responses to viral infections, in particular infections of the liver, to better understand the pathogenesis of the disease and to develop vaccines and effective antiviral therapies. 2. We evaluate how hepatic and systemic immune responses are regulated by the gastrointestinal microbiome.

Immunopathogenesis of viral hepatitis

Three human hepatitis viruses (HBV, HCV and HDV) are the causative agents for almost all cases of chronic viral hepatitis. Host immune responses play a significant role in both viral control and disease pathogenesis in all three infections. We take three approaches to study the immunopathogenesis of viral hepatitis:

  • We study immune responses of clinically well-characterized patients in different phases of chronic viral hepatitis before, during and after treatment.
  • We use animal models to address basic immunological questions that arise from translational studies. For example, we use mice to evaluate the effect of the gut microbiome on systemic and hepatic immune responses.
  • We employ in vitro models of primary cell cultures and viral infection to study innate immune responses.

Regulation of hepatic and systemic immune responses by the gut microbiome

The phenotype of all mammals - from rodents, to non-human primates to humans - is driven by the host genome and the microbial genome. We currently take the following approaches to better understand the effects of the microbiome on host fitness and, in particular, on immune responses.

  • Based on the concept that natural microbiota co-evolved with their respective hosts under evolutionary pressure and confer host fitness-promoting traits we have established a mouse model that combines the tractable genetics of regular laboratory mice with the gastrointestinal microbiota of wild mice. These mice show increased disease resistance upon influenza virus challenge and gastrointestinal carcinogenesis when compared to standard laboratory mice. Such models may lead to the identification of mechanisms of host physiology and disease resistance in the natural world, improve preclinical efficacy and safety testing, and more accurately reflect diseases in humans.
  • In a translational human immunology study, we are evaluating changes in the gut microbiome and in inflammatory status in HBV-infected women and uninfected controls who are prospectively followed during and after pregnancy. The aim of this research is to understand the causative mechanisms, predictive markers and risk factors for hepatitis B disease flares during pregnancy.

Applying our Research

This research will help decrease the burden of liver disease—in particular, chronic viral hepatitis—and the long-term consequences of chronic inflammation of the liver such as cancer. In addition, the basic immunological mechanisms that are being studied may be relevant to other diseases; for example, what we learn from the immune responses against hepatitis viruses can inform research on other pathogens and tumors that are also targeted by the immune system. Our research on the gastrointestinal microbiome will help us better understand how immune responses and inflammation are regulated.

Need for Further Study

Detailed knowledge on immune responses is key to understanding disease progression in chronic viral hepatitis, to assessing immune-modulatory therapies for HBV and HDV infection, and to developing prophylactic vaccines against HCV and HDV. It also advances our understanding of basic mechanisms of immune regulation in conditions of chronic antigen persistence, which is relevant for other infections and cancer.


  • Elected Member, Association of American Physicians, 2014
  • Elected Member, American Society for Clinical Investigation, 2004
  • Chief and Senior Investigator, Immunology Section, Liver Diseases Branch, NIDDK, NIH, 2004-present
  • Head and Tenure-Track Investigator, Immunology Section, Liver Diseases Branch, NIDDK, NIH, 1998-2004
  • Habilitation, Privatdozent of Immunology, Medizinische Hochschule Hannover, Germany, 1999
  • Clinical Fellowship and Research, Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Germany, 1995-1998
  • Postdoctoral Fellowship in Viral Immunology, The Scripps Research Institute, La Jolla, CA, 1993-1995
  • Medical Internship and Residency, Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Germany, 1991-1993
  • M.D., Medizinische Hochschule Hannover, Germany, 1991

Selected Publications

  1. Hild B, Dreier MS, Oh JH, McCulloch JA, Badger JH, Guo J, Thefaine CE, Umarova R, Hall KD, Gavrilova O, Rosshart SP, Trinchieri G, Rehermann B. Neonatal exposure to a wild-derived microbiome protects mice against diet-induced obesity. Nat Metab. 2021;3(8):1042-1057.

  2. Rosshart SP, Herz J, Vassallo BG, Hunter A, Wall MK, Badger JH, McCulloch JA, Anastasakis DG, Sarshad AA, Leonardi I, Collins N, Blatter JA, Han SJ, Tamoutounour S, Potapova S, Foster St Claire MB, Yuan W, Sen SK, Dreier MS, Hild B, Hafner M, Wang D, Iliev ID, Belkaid Y, Trinchieri G, Rehermann B. Laboratory mice born to wild mice have natural microbiota and model human immune responses. Science. 2019;365(6452).

  3. Nishio A, Bolte FJ, Takeda K, Park N, Yu ZX, Park H, Valdez K, Ghany MG, Rehermann B. Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection. Sci Transl Med. 2021;13(587).

  4. Kefalakes H, Horgan XJ, Jung MK, Amanakis G, Kapuria D, Bolte FJ, Kleiner DE, Koh C, Heller T, Rehermann B. Liver-Resident Bystander CD8+ T Cells Contribute to Liver Disease Pathogenesis in Chronic Hepatitis D Virus Infection. Gastroenterology. 2021.

  5. Bolte FJ, O'Keefe AC, Webb LM, Serti E, Rivera E, Liang TJ, Ghany M, Rehermann B. Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation. Gastroenterology. 2017;153(5):1392-1403.e2.

This page was last updated on October 14th, 2021